Gilead said it was ramping up production and aims to have more than 140,000 treatment courses by the end of May, more than 500,000 by October and more than 1 million by December.
conducted by the U.S. National Institute of Allergy and Infectious Diseases found patients given the experimental drug remdesivir recovered faster and may be less likely to die. Patients who received remdesivir had a 31% faster recovery time than those who received a placebo, the study found. Some evidence suggests the mortality rate was lower in those who got the drug, too, but it was not as statistically significant, researchers say.
While not a"knockout," White House coronavirus task force chief Dr. Anthony Fauci said the study results were"a very important proof of concept." President Donald Trump added of the test results, “But certainly . . . it's a positive, it's a very positive event.” The company is also attempting to develop other delivery methods for the drug, which is given via an IV and blocks an enzyme the virus uses to copy its genetic material. Gilead hopes to develop a shot that can be given outside o the hospital"or possibly an inhaled version," O'Day said.
"This medicine is not suitable for oral administration because of the way it is metabolized, but there are ways we can look at formulations potentially that would get us to earlier patients and patients outside the hospital setting," he said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead CEO says remdesivir available to coronavirus patients this week: 'We've donated the entire supply'Gilead Sciences coronavirus fighting drug will be in the hands of patients as early as this week, the biotechnology company's CEO said Sunday.
Read more »
Gilead gets emergency FDA authorization for remdesivir to treat coronavirus, Trump saysThe Food and Drug Administration has granted emergency use authorization for Gilead’s remdesivir drug to treat the coronavirus, President Donald Trump announced Friday.
Read more »
Gilead says it can produce 'several million' rounds of remdesivir coronavirus treatments next year“We’re just humbled and pleased by the results this week as a starting point for therapies in COVID-19.” Gilead CEO Daniel O’Day discussed the positive results released this week from 2 remdesivir studies.
Read more »
Gilead Lobbying Rose As Interest In COVID-19 Treatment ClimbedThe Food and Drug Administration authorized Friday the emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.
Read more »
Tesla CEO Elon Musk's coronavirus rant highlights just one of many hurdles automakers face in reopening plantsIn reopening plants, automakers face worker safety issues and must abide by local mandates, which Tesla CEO Elon Musk highlighted earlier this week. Then there are more complex problems.
Read more »